Indexado em
  • Banco de Dados de Periódicos Acadêmicos
  • Abra o Portão J
  • Genamics JournalSeek
  • JournalTOCs
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Scimago
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade de Hamdard
  • EBSCO AZ
  • OCLC- WorldCat
  • publons
  • MIAR
  • Comissão de Bolsas Universitárias
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • Google Scholar
Compartilhe esta página

Abstrato

Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine

Fumito Ito and Sharon S Evans

A lack of effective immune response against cancer is one of the major risk factors for developing local recurrence and distant metastases after curative resectional surgery. Prior studies revealed that systemic antitumor immunity is elicited by radiofrequency ablation (RFA) of tumor lesions, which is mainly considered a palliative procedure for unresectable tumors or for inoperable patients. Recently, we discovered an oncological benefit that depends on the adaptive arm of the antitumor immune response when RFA is performed in a neoadjuvant setting prior to surgical resection in preclinical murine models.